Decitabine

2:07
International ABNL-MARRO trial for MDS/MPN overlap syndromes
Valeria Santini
2:57
Promising venetoclax updates in AML: DEC10-VEN, CLAD/LDAC, antifungals
Marina Konopleva
2:07
Onvansertib with cytarabine or decitabine for R/R AML
Amer Zeidan
3:35
Onvansertib with cytarabine or decitabine for R/R AML
Amer Zeidan
4:09
QuANTUM-R: quizartinib looks promising for FLT3-ITD mutated AML
Naval Daver
2:38
MPN updates: personalized prognostication, novel treatments & more
Ruben Mesa
1:48
A new era for elderly AML patients
Farhad Ravandi
3:32
Venetoclax in AML updates: approval & combinations
Marina Konopleva
2:45
Identifying genetic mutations for diagnosing MDS
Torsten Haferlach
5:06
Personalized therapy for MDS: Advancements and the future
Torsten Haferlach
4:19
Intervening on time: how hypomethylating agents can prevent transition to AML
Srdan Verstovsek
1:34
The importance of quickly spotting the signs of AML
Srdan Verstovsek
2:57
Genetic biomarkers of response to venetoclax in AML
Marina Konopleva
3:05
Current research in elderly, untreated AML: venetoclax combinations
Marina Konopleva
3:20
Venetoclax combinations effective in elderly AML
Marina Konopleva
1:39
Current landscape and future directions for lower-risk MDS treatment
David Steensma
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals